Literature DB >> 24715655

Introduction, rationale, and methodology.

Jeffrey J Olson1, Timothy Charles Ryken, Steven N Kalkanis.   

Abstract

Mesh：

Year:  2014        PMID： 24715655     DOI： 10.1007/s11060-013-1329-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  11 in total

Review 1.  Antiangiogenic therapies in glioblastoma multiforme.

Authors:  Mairéad G McNamara; Warren P Mason
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

2.  Guidelines for the treatment of newly diagnosed glioblastoma: introduction.

Authors:  Jeffrey J Olson; Timothy Ryken
Journal:  J Neurooncol       Date:  2008-05-23       Impact factor: 4.130

3.  Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.

Authors:  Amy S Darefsky; Joseph T King; Robert Dubrow
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

Review 4.  Does extent of resection of a glioblastoma matter?

Authors:  Michael A Vogelbaum
Journal:  Clin Neurosurg       Date:  2012

5.  Improved survival time trends for glioblastoma using the SEER 17 population-based registries.

Authors:  Matthew Koshy; John L Villano; Therese A Dolecek; Andrew Howard; Usama Mahmood; Steven J Chmura; Ralph R Weichselbaum; Bridget J McCarthy
Journal:  J Neurooncol       Date:  2011-10-09       Impact factor: 4.130

Review 6.  Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies.

Authors:  K Masui; T F Cloughesy; P S Mischel
Journal:  Neuropathol Appl Neurobiol       Date:  2012-06       Impact factor: 8.090

Review 7.  New molecularly targeted therapies for glioblastoma multiforme.

Authors:  Jiri Polivka; Jiri Polivka; Vladimir Rohan; Ondrej Topolcan; Jiri Ferda
Journal:  Anticancer Res       Date:  2012-07       Impact factor: 2.480

8.  Surgical management of cervical degenerative disease: the evidence related to indications, impact, and outcome.

Authors:  Michael G Fehlings; Babak Arvin
Journal:  J Neurosurg Spine       Date:  2009-08

9.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

10.  Evidence-based clinical practice parameter guidelines for the treatment of patients with metastatic brain tumors: introduction.

Authors:  Steven N Kalkanis; Mark E Linskey
Journal:  J Neurooncol       Date:  2009-12-03       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.